During the 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the AML Hub spoke to Arnon Nagler, Vice Chair of the Acute Leukaemia Working Party of the EBMT. We asked, Which is more relevant for allo-HSCT outcome: cytogenetic risk or MRD status?